文献速递胸部肿瘤

纳武利尤单抗治疗晚期非小细胞肺癌患者的安全性、疗效及患者报告的健康相关生活质量和症状负担,包括70岁及以上或体能状态差的患者(CheckMate 153)

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
PubMed 文献 · J Thorac Oncol · 2019-05-20

CheckMate 153是一项3B/4期研究,评估纳武利尤单抗在经治晚期非小细胞肺癌患者中的表现,允许入组高龄或ECOG PS 2分等预后不良患者。1426例接受治疗患者中,556例(39%)年龄≥70岁,128例(9%)ECOG PS为2。各亚组与总体人群中选择性3-5级治疗相关不良事件发生率(6%-9%)和3或4级TRAE发生率(12%-14%)相似,患者报告结局总体改善。

要点

  • 1426例接受纳武利尤单抗治疗,556例(39%)年龄≥70岁,128例(9%)ECOG PS为2。
  • 各亚组与总体人群中选择性3-5级TRAE发生率6%-9%,3或4级TRAE发生率12%-14%,相似。
  • 中位总生存期:总体人群9.1个月,≥70岁患者10.3个月,ECOG PS 2患者4.0个月。

核心结论

  • 这项以社区为基础的大型研究数据与注册研究一致,该研究纳入70岁及以上和ECOG PS为2的患者。
  • ECOG PS为2患者的中位总生存期如预期低于总体人群,但与历史数据相当。

研究设计与样本

  • CheckMate 153(NCT02066636)是一项3B/4期研究,评估纳武利尤单抗在经治晚期非小细胞肺癌患者中的表现。
  • 入组标准允许高龄或ECOG PS评分降低等预后不良特征的患者入组,这些患者通常在随机对照试验中代表性不足或被排除。
  • 患者为IIIB或IV期非小细胞肺癌,ECOG PS为0至2,至少接受过一种全身治疗后疾病进展,接受纳武利尤单抗3 mg/kg每2周一次治疗,直至疾病进展、出现不可接受的毒性或撤回知情同意。
  • 主要终点为选择性3至5级治疗相关不良事件的发生率。

主要发现

  • 1426例接受治疗患者中,556例(39%)年龄70岁及以上,128例(9%)ECOG PS为2。
  • 中位治疗持续时间为3.2个月。
  • 各亚组和总体人群中,选择性3至5级TRAE发生率(6%-9%)和3或4级TRAE发生率(12%-14%)相似。
  • 记录到1例5级TRAE。
  • 中位总生存期在总体人群(9.1个月)和70岁及以上患者(10.3个月)中相当,但在ECOG PS为2的患者中较短(4.0个月)。

关键数值与推荐

  • 纳武利尤单抗给药方案为3 mg/kg每2周一次。
  • 选择性3至5级TRAE发生率在各亚组和总体人群中为6%-9%。
  • 3或4级TRAE发生率在各亚组和总体人群中为12%-14%。
  • 中位总生存期:总体人群9.1个月,70岁及以上患者10.3个月,ECOG PS为2患者4.0个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed enrollment of patients with poor prognostic features of advanced age or diminished Eastern Cooperative Oncology Group performance status (ECOG PS), which are typically underrepresented in or excluded from randomized controlled trials. METHODS: Patients with stage IIIB or IV NSCLC and an ECOG PS of 0 to 2 with disease progression after at least one systemic therapy received nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal. The primary end point was the incidence of grade 3 to 5 select treatment-related adverse events (TRAEs). RESULTS: Among 1426 treated patients, 556 (39%) were aged 70 years or older and 128 (9%) had an ECOG PS of 2. The median treatment duration was 3.2 months. Across subgroups and the overall population, the incidences of select grade 3 to 5 TRAEs (6%-9%) and grade 3 or 4 TRAEs (12%-14%) were similar. One grade 5 TRAE was documented. The median overall survival time was comparable in the overall population (9.1 months) and patients aged 70 years or older (10.3 months) but shorter in patients with an ECOG PS of 2 (4.0 months). Patient-reported outcomes generally improved. CONCLUSIONS: Data from this large predominantly community-based study, which included patients aged 70 years or older and with an ECOG PS of 2, are consistent with registrational studies. As expected, the median overall survival for patients with an ECOG PS of 2 was lower than for the overall population but comparable with historical data.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Spigel DR, McCleod M, Jotte RM, et al. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). J Thorac Oncol. 2019. PMID: 31121324. doi:10.1016/j.jtho.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。